Tsiachris Dimitris, Botis Michail, Doundoulakis Ioannis, Bartsioka Lamprini Iro, Tsioufis Panagiotis, Kordalis Athanasios, Antoniou Christos-Konstantinos, Tsioufis Konstantinos, Gatzoulis Konstantinos A
First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, "Hippokration" Hospital, 11527 Athens, Greece.
Athens Heart Center, Athens Medical Center, 15125 Athens, Greece.
Diagnostics (Basel). 2023 Sep 29;13(19):3094. doi: 10.3390/diagnostics13193094.
Premature ventricular complexes (PVCs) are frequently encountered in clinical practice. The association of PVCs with adverse cardiovascular outcomes is well established in the context of structural heart disease, yet not so much in the absence of structural heart disease. However, cardiac magnetic resonance (CMR) seems to contribute prognostically in the latter subgroup. PVC-induced myocardial dysfunction refers to the impairment of ventricular function due to PVCs and is mostly associated with a PVC burden > 10%. Surface 12-lead ECG has long been used to localize the anatomic site of origin and multiple algorithms have been developed to differentiate between right ventricular and left ventricular outflow tract (RVOT and LVOT, respectively) origin. Novel algorithms include alternative ECG lead configurations and, lately, sophisticated artificial intelligence methods have been utilized to determine the origins of outflow tract arrhythmias. The decision to therapeutically address PVCs should be made upon the presence of symptoms or the development of PVC-induced myocardial dysfunction. Therapeutic modalities include pharmacological therapy (I-C antiarrhythmic drugs and beta blockers), as well as catheter ablation, which has demonstrated superior efficacy and safety.
室性早搏(PVCs)在临床实践中经常遇到。在结构性心脏病的背景下,PVCs与不良心血管结局之间的关联已得到充分证实,但在无结构性心脏病的情况下并非如此。然而,心脏磁共振成像(CMR)似乎对后一亚组患者的预后有影响。PVC诱导的心肌功能障碍是指由于PVCs导致的心室功能损害,主要与PVC负荷>10%有关。长期以来,体表12导联心电图一直用于定位起源的解剖部位,并且已经开发了多种算法来区分右心室和左心室流出道(分别为RVOT和LVOT)起源。新的算法包括替代的心电图导联配置,最近,复杂的人工智能方法已被用于确定流出道心律失常的起源。对于PVCs是否进行治疗应根据症状的出现或PVC诱导的心肌功能障碍的发展来决定。治疗方式包括药物治疗(I-C类抗心律失常药物和β受体阻滞剂)以及导管消融,导管消融已显示出更高的疗效和安全性。